Calamos Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Calamos Advisors LLC

  • $14.5 Billion
  • Q1 2024

A detailed history of Calamos Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Calamos Advisors LLC holds 48,124 shares of VRTX stock, worth $22.6 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
48,124
Previous 69,172 30.43%
Holding current value
$22.6 Million
Previous $28.1 Million 28.53%
% of portfolio
0.14%
Previous 0.2%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
SELL
$407.69 - $446.08 $8.58 Million - $9.39 Million
-21,048 Reduced 30.43%
48,124 $20.1 Million
Q4 2023

Jan 31, 2024
SELL
$343.0 - $410.68 $316,589 - $379,057
-923 Reduced 1.32%
69,172 $28.1 Million
Q2 2023

Jul 28, 2023
SELL
$314.42 - $351.91 $3.61 Million - $4.04 Million
-11,477 Reduced 14.07%
70,095 $24.7 Million
Q1 2023

May 03, 2023
SELL
$283.23 - $323.1 $2.88 Million - $3.29 Million
-10,185 Reduced 11.1%
81,572 $25.7 Million
Q4 2022

Jan 25, 2023
SELL
$285.76 - $321.48 $4.62 Million - $5.2 Million
-16,171 Reduced 14.98%
91,757 $0
Q3 2022

Oct 24, 2022
BUY
$273.83 - $305.53 $10,131 - $11,304
37 Added 0.03%
107,928 $31.2 Million
Q2 2022

Aug 01, 2022
BUY
$234.96 - $292.55 $682,323 - $849,565
2,904 Added 2.77%
107,891 $30.4 Million
Q1 2022

May 03, 2022
BUY
$221.42 - $260.97 $3.06 Million - $3.61 Million
13,837 Added 15.18%
104,987 $27.4 Million
Q4 2021

Feb 01, 2022
SELL
$177.01 - $223.45 $3.51 Million - $4.43 Million
-19,807 Reduced 17.85%
91,150 $20 Million
Q3 2021

Oct 26, 2021
SELL
$181.39 - $202.99 $3.09 Million - $3.46 Million
-17,046 Reduced 13.32%
110,957 $20.1 Million
Q2 2021

Jul 22, 2021
SELL
$187.49 - $221.1 $13.4 Million - $15.8 Million
-71,266 Reduced 35.76%
128,003 $25.8 Million
Q1 2021

Apr 12, 2021
BUY
$207.02 - $241.31 $11.8 Million - $13.8 Million
57,190 Added 40.25%
199,269 $42.8 Million
Q4 2020

Jan 27, 2021
SELL
$207.01 - $276.09 $843,772 - $1.13 Million
-4,076 Reduced 2.79%
142,079 $33.6 Million
Q3 2020

Oct 26, 2020
SELL
$255.65 - $303.1 $6.59 Million - $7.82 Million
-25,789 Reduced 15.0%
146,155 $39.8 Million
Q2 2020

Jul 27, 2020
BUY
$225.48 - $295.8 $12.9 Million - $16.9 Million
57,288 Added 49.97%
171,944 $49.9 Million
Q1 2020

Apr 28, 2020
BUY
$199.77 - $247.81 $14.6 Million - $18.1 Million
72,931 Added 174.79%
114,656 $27.3 Million
Q4 2019

Jan 15, 2020
SELL
$166.71 - $223.91 $121,198 - $162,782
-727 Reduced 1.71%
41,725 $9.14 Million
Q3 2019

Oct 21, 2019
BUY
$166.23 - $187.09 $611,892 - $688,678
3,681 Added 9.49%
42,452 $7.19 Million
Q2 2019

Aug 07, 2019
BUY
$164.61 - $190.37 $317,368 - $367,033
1,928 Added 5.23%
38,771 $7.11 Million
Q1 2019

Apr 12, 2019
BUY
$163.73 - $194.7 $66,801 - $79,437
408 Added 1.12%
36,843 $6.78 Million
Q4 2018

Jan 24, 2019
BUY
$151.91 - $192.21 $828,669 - $1.05 Million
5,455 Added 17.61%
36,435 $6.04 Million
Q3 2018

Oct 22, 2018
SELL
$167.73 - $192.74 $528,014 - $606,745
-3,148 Reduced 9.22%
30,980 $5.97 Million
Q2 2018

Jul 17, 2018
BUY
$145.72 - $169.96 $586,960 - $684,598
4,028 Added 13.38%
34,128 $5.8 Million
Q1 2018

Apr 13, 2018
BUY
$151.6 - $177.13 $214,968 - $251,170
1,418 Added 4.94%
30,100 $4.91 Million
Q4 2017

Feb 13, 2018
SELL
$137.28 - $155.55 $75,092 - $85,085
-547 Reduced 1.87%
28,682 $4.3 Million
Q3 2017

Oct 25, 2017
BUY
$148.13 - $162.24 $151,388 - $165,809
1,022 Added 3.62%
29,229 $4.44 Million
Q2 2017

Aug 09, 2017
BUY
N/A
28,207
28,207 $3.64 Million

Others Institutions Holding VRTX

# of Institutions
1,623
Shares Held
222M
Call Options Held
1.35M
Put Options Held
1.49M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Calamos Advisors LLC Portfolio

Follow Calamos Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email